Biosynex Share Price OTC Markets

BSYXF

FR0011005933

Medical Equipment, Supplies & Distribution

End-of-day quote OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

06-11	Triple update for Biosynex
06-10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI

News in other languages: Biosynex

06-13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
06-11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
06-11	Une bonne grosse purge avant SpaceX
06-11	Triple actualité pour Biosynex
06-11	BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE

More news

Managers and Directors: Biosynex

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	23/06/2015
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	31/12/2014
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	23/06/2015
Thomas Lamy BRD	Director/Board Member	-	23/06/2015
Larry Abensur CHM	Chairman	71	23/06/2015

More insiders

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-.--%	-.--%	-	-	18.81M
GUARDANT HEALTH, INC.	+0.56%	-2.61%	+235.49%	+310.94%	20.67B
BIOMÉRIEUX	-0.48%	+2.54%	-38.64%	-22.63%	9.85B
LANTHEUS HOLDINGS, INC.	+2.36%	+1.85%	+53.31%	+20.60%	7B
10X GENOMICS, INC.	-1.66%	+2.36%	+260.00%	-27.26%	5.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.36%	+3.63%	-17.20%	-23.46%	5.23B
ANDON HEALTH CO., LTD.	+10.00%	+34.69%	+101.94%	+124.62%	4.9B
CARIS LIFE SCIENCES, INC.	+0.06%	-2.94%	-45.38%	-	4.66B
DIASORIN S.P.A.	+0.98%	+0.75%	-21.35%	-25.05%	4.2B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.66%	+4.71%	-15.83%	-39.84%	2.72B
Average	+0.95%	+5.83%	+56.93%	+39.74%	7.2B
Weighted average by Cap.	+0.96%	+3.67%	+98.29%	+107.61%

See all sector performances

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement and Estimates

More financial data

As early as today, start finding the best investment opportunities!

Market Cap	16.44M 18.81M 15.17M 13.98M 26.36M 1.81B 26.94M 181M 71.32M 887M 70.65M 69.1M 3.05B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	69.63M 79.68M 64.25M 59.23M 112M 7.67B 114M 768M 302M 3.76B 299M 293M 12.94B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

06-11	Triple update for Biosynex
06-10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-25	Paris climbs on hopes of Middle East de-escalation
05-25	Biosynex announces the divestment of its molecular biology business
05-24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Biosynex postpones publication of annual accounts
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-24	Observation period extended for Biosynex
02-06	A Biosynex Subsidiary to Receive $1.8 Million Grant
02-06	Aperam, Société Générale, Stellantis: Key Stocks to Watch Today in Paris

23/10/24	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
27/04/23	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
13/04/23	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
15/03/23	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
31/01/23	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

	2024	2025
Net sales	101M 116M 93.35M 86.05M 162M 11.15B 166M 1.12B 439M 5.46B 435M 425M 18.8B	95.19M 109M 87.84M 80.97M 153M 10.49B 156M 1.05B 413M 5.14B 409M 400M 17.69B
Net income	-43.33M -49.58M -39.99M -36.86M -69.47M -4.78B -71.01M -478M -188M -2.34B -186M -182M -8.05B	-58.22M -66.63M -53.73M -49.52M -93.34M -6.42B -95.41M -642M -253M -3.14B -250M -245M -10.82B
Net Debt	52.94M 60.57M 48.85M 45.03M 84.86M 5.83B 86.75M 584M 230M 2.86B 227M 222M 9.84B	53.19M 60.87M 49.08M 45.24M 85.27M 5.86B 87.16M 587M 231M 2.87B 229M 224M 9.88B

Biosynex Share Price OTC Markets

Stocks

BSYXF

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Managers and Directors: Biosynex

Diagnostic & Testing Substances

Financials

Company Profile

Income Statement and Estimates